Blue Oak Pharmaceuticals
Tom Large has a diverse work experience spanning over several decades. Tom began their career in 1985 as a Postdoctoral Fellow at the Howard Hughes Medical Institute. From there, they moved on to become an Assistant Professor at Case Western Reserve University School of Medicine in 1989. In 1997, they joined Eli Lilly and Company, where they held various roles, including Head and Group Manager. In 2007, they transitioned to Sunovion Pharmaceuticals Inc. as Senior Vice President of Preclinical Research and Translational Medicine. Most recently, in 2016, Tom co-founded Blue Oak Pharmaceuticals and assumed the position of CEO.
Tom Large attended Northwestern University from 1976 to 1985, during which they pursued a BA/MS/PhD degree in Neuroscience and Physiology.
This person is not in any teams
Blue Oak Pharmaceuticals
Blue Oak Pharmaceuticals is a pharmaceutical company that is committed to finding the next generation of drugs for brain disorders. They believe that first-in-class drugs will be discovered by integrating novel, custom-designed privileged chemotypes with validated in vivo systems neurobiology assays and brain circuit imaging.Blue Oak drug huntersare experts in the systems neurobiology of brain disorders, medicinal chemistry, and informatics. Their productivity integrates a “global research team” that integrates established partners with cutting-edge technologies in behavioral profiling, synthetic chemistry, and brain imaging. They advance first-in-class clinical candidates to early phase proof-of-concept studies using translational medicine biomarkers for brain circuit activity.It was founded in 2016 and is headquartered in Waltham, Massachusetts.